Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 2/20 | 0.40 |
| ▸ | GABRD | O14764 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRE | P78334 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256558 | 0.83 | NR4A3 (0.45) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL27843124 | 0.80 | NR4A3 (0.46) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL31053372 | 0.80 | NR4A3 (0.43) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL21960891 | 0.80 | NR4A3 (0.43) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL16229739 | 0.79 | RAB9A (0.48) | KDM4EALDH1A1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL22534352 | 0.78 | NR4A3 (0.51) | NR4A3KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL27737816 | 0.78 | NR4A3 (0.51) | NR4A3GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31053389 | 0.78 | NR4A3 (0.41) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL28396213 | 0.77 | NR4A3 (0.43) | NR4A3L3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL3294253 | 0.77 | NR4A3 (0.54) | NR4A3GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | NR4A3 2776/4885GABRP 1435/4885GABRD 1034/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | NR4A3 3040/4885GABRP 2629/4885GABRD 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.